La chaîne d'options affiche les données clés des options sur actions de Bright Minds Biosciences à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Bright Minds Biosciences..

Bright Minds Biosciences (NASDAQ:DRUG) Stock, Chaîne d'Options

Bright Minds Biosciences

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences Inc

Drugs Made In America Acquisition II Corp. - Unit

Drugs Made In America Acquisition II Corp

Drugs Made In America Acquisition Corp. - Units

Drugs Made In America Acquisition Corp

DRUG FREE SOLUTION INC by Drug Free Solution Inc.

Drug Free Solution Inc

Drugs Made In America Acquisition Corp. - Ordinary Shares

Drugs Made In America Acquisition Corp. - Rights

News

Management

Press Releases

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

Health Care

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

General

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Bright Minds Biosciences to Present at Upcoming Conferences

Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model

Offerings

BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING

CSE:DRUG

DRUG

ADC Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

enGene Holdings

I-MAB

Immuneering Corporation - Class A Common Stock

Immuneering

Invivyd

Jade Biosciences

Kamada

Keros Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Neurogene

Ocugen

ProKidney Corp. - Class A Ordinary Shares

ProKidney

PureTech Health plc - American Depositary Shares

PureTech Health

Rocket Pharmaceuticals, Inc. - Common Stock

Comments

Bright Minds Biosciences

Bright Minds Biosciences (DRUG) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL